Ares Management Corporation

---

ticker: ARES step: 01 generated: 2026-05-28 source: coverage-next-full (transcript-free)

Ares Management (ARES) — Step 01: Business Model & Value-Chain Map

Key Findings

ARES is a global alternative asset manager that monetizes investor capital through three fee mechanics: (1) management fees on AUM (~78% of fee-related revenue, recurring), (2) realized performance income / carried interest (~17%, lumpy and harvest-dependent), and (3) Aspida insurance / investment income (~5%, growing structural [S2][S4][S7]). Four investment groups: Credit (65% of AUM), Real Assets (22%, doubled post-GCP), Secondaries (7%), Private Equity (4%) [S2]. The business is structurally levered to: long-duration capital (locked-up drawdown funds and perpetual capital), high incremental margins on incremental AUM, and the maturation of the Aspida insurance flywheel. Net positive for thesis — the business model is durable, scalable, and the perpetual-capital build-out is the key strategic asset to track.

Implications for Thesis and Valuation

1. Management fees are the durable cash engine (~$3.7B FY2025 [S2]) — these grow with FPAUM at ~22% CAGR and don't compress meaningfully (vs. traditional active managers where fee rates are eroding 1-2bps/year).
2. Performance income is the variance source — Q4 2025 missed because performance harvest timing slipped; the long-cycle carry pool (NAPI) is the buffer.
3. Aspida is under-modeled in consensus — at maturity (5+ years), Aspida could provide $50B+ of captive credit deployment, materially increasing the AUM compounding rate beyond third-party fundraising alone.
4. Real Assets segment optionality — Doubled in 2025 (GCP). FY2026 will reveal whether GCP synergies are real (positive thesis input) or whether GCP integration generates margin drag (negative input).
5. The model is capital-light in steady state but acquisition-heavy in growth phase (GCP, Crescent Point, Landmark, Black Creek, Aspida build-out).

Objective

Map the ARES business model, identify how each fee mechanism produces shareholder economics, and characterize value-chain position relative to LPs, portfolio companies, and the broader alternative asset ecosystem.

Narrative Analysis

What ARES Does

ARES raises capital from institutional LPs (pension funds, sovereign wealth, insurance companies, endowments) and increasingly from wealth-channel retail investors. It invests this capital through dedicated investment vehicles (drawdown funds, perpetual capital structures, BDCs, interval funds, etc.) and earns:

1. Management fees — Typically 75-150 bps annually on FPAUM. Blended effective fee rate ≈ 95-100 bps [A09]. These are contractual, recurring, and accrue regardless of investment performance during the fund's life.
2. Performance fees / carried interest — A share (typically 10-20%) of investment profits above a preferred return threshold (typically 6-8% IRR). Recognized when funds realize gains via portfolio company exits, refinancings, dispositions. The accrued-but-unrealized portion appears on the balance sheet as Net Accrued Performance Income (NAPI), historically $1.0-1.2B at quarter-end [S2].
3. Aspida investment income — Aspida originates fixed annuities, deploys proceeds into Ares-managed credit strategies, and earns the spread. ARES captures both the management fee on Aspida's deployed capital AND a share of Aspida's net investment spread [S5][S15].

Value Chain Position

Capital Sources                Ares Management Platform           Deployment / Borrowers
─────────────────              ─────────────────────────          ──────────────────────
Institutional LPs              ┌────────────────────────┐
(pension, sovereign,           │  Credit Group ($407B)  │ ─────►  US/EU mid-mkt
endowment, insurance)          │  - Direct Lending      │         leveraged loans,
                               │  - Alt Credit          │         CLOs, opportunistic
Wealth channel /          ────►│  - High Yield/Liquid   │         credit
retail investors               │  - CLOs                │
(via interval funds,           ├────────────────────────┤
non-traded BDCs)               │  Real Assets ($139B)   │ ─────►  Real estate (equity
                               │  - RE Equity + Debt    │         + debt), infra debt,
ARES balance sheet         ───►│  - Infrastructure      │         climate infra,
(via Aspida fixed annuities,   │  - Climate Infra       │         post-GCP Asia
employee co-invest)            ├────────────────────────┤
                               │  Secondaries ($42B)    │ ─────►  LP secondaries +
                               │  - LP-led              │         GP continuation
                               │  - GP-led continuation │         vehicles
                               ├────────────────────────┤
                               │  Private Equity ($25B) │ ─────►  Mid-mkt PE +
                               │  - Mid-Mkt PE          │         special opp PE
                               │  - Special Opp         │
                               └────────────────────────┘

   ARES extracts:              ARES employs ~3,200       Returns capital +
   - Mgmt fees on FPAUM        people across origination,  performance to LPs
   - Realized perf income      portfolio mgmt, distribution
   - Aspida net spread         + functional support
   - Aspida BS earnings (NCI)

The Aspida Flywheel — Strategic Centerpiece

ARES acquired Aspida (then a small insurance platform) and progressively built it into a fixed-annuity reinsurance business. The flywheel:

1. Aspida issues fixed-rate annuities to retail investors → permanent liability with multi-decade duration
2. Aspida invests proceeds into Ares Credit Group strategies → ARES earns management fees on this captive capital
3. Aspida earns the net spread between annuity rate (~5%) and Ares-deployed credit yields (~8-10%)
4. Both the management fee AND the spread accrue to ARES economics

This is structurally analogous to Apollo/Athene ($300B+ insurance flywheel) and KKR/Global Atlantic ($200B). Aspida is currently smaller ($15-20B+) but growing rapidly [S2][S5][S15]. Critically: Aspida-deployed AUM is "perpetual capital" by definition — annuity liabilities don't redeem like LP fund commitments.

Perpetual Capital — The Margin Multiplier

Perpetual capital AUM reached $200B at YE2025 (32% of total), growing 50% YoY [S2]. Sources:

• Ares Capital Corp (ARCC) — the largest publicly-traded BDC; permanent capital structure
• Aspida insurance balance sheet (above)
• Ares Strategic Income Fund (ASIF) — interval fund
• Ares Industrial Income Fund (AIIF) — interval fund / NTREIT
• AREIT (non-traded REIT vehicles)
• Core+ / open-end real estate funds
• GP-led continuation vehicles (some perpetual)

Strategic importance: perpetual capital eliminates the "fundraising treadmill" that traditional drawdown funds require. Once raised, perpetual capital compounds management fees indefinitely without LP redemption risk. Best-in-class alts manager (Blue Owl/OWL) operates at ~80% perpetual; ARES at 32% has significant room to inflect [S7].

Where Margin Comes From

• Management fees flow to a structurally high-margin business — incremental AUM doesn't require linear headcount growth
• FRE margin 41.7% FY2025 [S8]; BX achieves 60%+ at scale [Peer Universe]
• Path to higher FRE margin: scale on existing platform + slower headcount growth than AUM growth
• Performance-fee revenue ~50% offset by perf-fee comp — only half is net economic value to shareholders [S2]
• Aspida investment income drops through with high incremental margin (spread is fairly clean)

Secondary Track Consideration

ARES has an insurance subsidiary (Aspida) and significant insurance-cycle exposure on a consolidated basis. However, the dominant economics are asset management fees and carry, not insurance underwriting. The Asset Manager — Alternative track is unambiguously primary. The insurance dimension is a key feature (flywheel) but does not warrant a primary insurer track.

Evidence and Sources

• Segment AUM at YE2025: Credit $406.9B, Real Assets $139.1B, Secondaries $42.1B, PE $25.3B [S2]
• Capital raised FY2025: $113.2B across 190+ vehicles [S2]
• Capital deployed FY2025: $145.8B including $69.1B from drawdown funds [S2]
• Q1 FY2026 fundraising: ~$29.5B (record quarter); $20.4B (69%) to Credit [S4]
• Perpetual capital growth: $133B (YE24) → $200B (YE25) → $215B (Q1 26) [S2][S4]
• Management fees crossed $1B in a single quarter for first time in Q1 2026 [S4]

Assumption Register Updates

New entries: A05 (Credit Group dominance), A06 (GCP doubling Real Assets). See ARES_assumption_register.md.

Tables and Calculations

Revenue Mix Estimate (FY2025)

Revenue Component	Est. $B	% of fee revenue	Recurring?
Management fees	3.70	~78%	Yes (subject to AUM levels)
Realized performance income (gross)	~0.80	~17%	No (harvest-dependent)
Aspida + other investment income	~0.25	~5%	Mixed
Fee-related revenue total	~4.75	100%
(Less: GAAP gross-up from Consolidated Funds)	nm
GAAP Revenue (XBRL)	4.76		[S3]

(Note: GAAP "Total Revenues" in XBRL approximately equal to the sum of fee-related streams here — broadly consistent.)

Customer / LP Concentration

LP Bucket	Estimated % of AUM	Notes
Pension funds (corporate + public)	~25%	Long-tenured relationships, sticky
Sovereign wealth + government investment funds	~20%	Strategic, very long-cycle
Insurance companies	~15%	Some captive (Aspida), some third-party
Endowments + foundations	~10%	Smaller per-LP ticket but high retention
Family offices + HNW	~10%	Growing channel
Wealth channel (retail, intermediated)	~10%	Fastest-growing; supplemental distribution fees +$17.9M YoY [S2]
Ares balance sheet + Aspida	~10%	Captive

ARES discloses limited LP concentration data; the above is industry-typical for a top-5 alts manager.

Geographic Mix (FY2025 post-GCP)

Region	AUM share (estimate)	Notes
North America	~70%	Historical core
Europe	~15%	Long-tenured; EU direct lending franchise
Asia-Pacific	~10%	Doubled post-GCP (Japan logistics, etc.)
Other / Emerging	~5%	LATAM, EMEA emerging via GCP

Pre-GCP this was ~80% North America, ~15% Europe, ~5% Other. GCP shifted the geographic mix toward Asia.

Open Questions and Data Gaps

1. Aspida total assets and projected scale path — Granular disclosure limited; need to triangulate from consolidated B/S movements
2. Performance fee cadence by fund vintage — Material for forecasting; not in summary supplements
3. GCP cost-synergies trajectory — Not yet quantified by management
4. Wealth-channel AUM precise breakdown — Growing but exact share unclear

Next-Step Dependencies

Step 02 (industry/competitive) will leverage the four-segment and Aspida-flywheel framing established here. Step 03 (revenue architecture) will quantify the fee-rate by segment. Step 06 (balance sheet) will assess Aspida consolidation impact.

Source Index

Tag	Document or URL	Section / Page / Slide	Date	Notes
[S2]	ARES 10-K FY2025	Item 1 (Business); MD&A; segment footnote	2026-02-25	Four segments, AUM mix, fundraising
[S3]	SEC XBRL	xbrl_summary.md	2026-05-28	GAAP revenue cross-check
[S4]	ARES Q1 2026 8-K Ex 99.2	Earnings release	2026-05-01	Q1 fundraising mix, AUM growth
[S5]	ARES 10-K FY2024	Item 1	2025-02-27	Pre-GCP business mix; Aspida history
[S7]	ARES investor presentation	Perpetual capital trajectory	2026-05-28	$200B perpetual capital data
[S8]	ARES Q4 2025 8-K	FY2025 FRE margin disclosure	2026-02	FRE margin 41.7%
[S14]	BusinessWire GCP closing	2025-03-03 release	2025-03-03	GCP integration confirmation
[S15]	AGM Alts Weekly + industry research	Peer flywheel benchmarks	2026-05-03	APO/Athene + KKR/GA comparators

---

ticker: ARES step: 04 generated: 2026-05-28 source: coverage-next-full (transcript-free)

ARES — Step 04: Financial Quality & Adversarial Sweep

Key Findings

ARES financial statements are clean from an accounting-integrity standpoint — no restatements in recent history, Big Four auditor (Ernst & Young) [S2], standard non-GAAP measures (FRE, RI, DE) clearly bridged to GAAP, segment disclosures comprehensive. GAAP volatility is structural, not a quality concern — Consolidated Funds (CLOs and AOG-consolidated entities) inflate the balance sheet by ~$20B+ and inject swing in operating income via fair-value mark adjustments [S3]. Adversarial sweep is mild: no active short reports specific to ARES, no SEC enforcement actions, no whistleblower allegations identified. The primary bear narrative is sector-wide — the "$265B private credit meltdown" framing (Fortune March 2026) [S11] which paints all alt managers (not just ARES) as overvalued/over-extended. Watch items: (a) insider open-market buying = 0 during the March 2026 drawdown, signaling neither conviction nor concern from management [S10]; (b) FY2025 FRE margin printed 41.7% — below the 43%+ peak in FY2023 [S2][S8], a small compression flag worth monitoring; (c) GCP step-up created $3.4B of new goodwill + intangibles in FY2025 [S3] — substantial PPA load to track for impairment over time. Net neutral for thesis — quality is solid but no positive surprises.

Implications for Thesis and Valuation

1. Use non-GAAP FRE / DE / RI for valuation — GAAP figures are not the right lens.
2. Goodwill + intangibles surveillance is a forward concern given the $3.4B GCP step-up; any FY2026/2027 impairment would be a meaningful negative signal.
3. FRE margin compression watch — the FY25 41.7% vs FY23 43%+ is small but bears monitoring; further compression below 40% would challenge thesis.
4. No accounting reason to discount the cited DE per share number — ARES has a multi-year track record of clean bridges between GAAP and non-GAAP.
5. Adversarial sweep gives no specific bear — but the sector-wide private-credit narrative remains a material macro overhang.

Objective

Test the quality of ARES's reported financials and conduct an adversarial sweep — short reports, lawsuits, regulatory actions, accounting irregularities — to surface any specific bear thesis the consensus may be missing.

Narrative Analysis

Earnings Quality

Auditor: Ernst & Young LLP — Big Four; no auditor changes recently [S2]. EY has audited ARES since at least 2014 IPO.

Restatements: None identified in the FY2023, FY2024, or FY2025 10-Ks.

Internal controls: Standard Section 404 certification by CEO Michael Arougheti and CFO Jarrod Phillips; no material weaknesses disclosed in FY2025 10-K [S2].

Critical accounting estimates (per 10-K):

1. Performance-fee recognition (revenue-recognition assumption on harvest timing)
2. Investments-at-fair-value classification (Level 3 inputs material)
3. Goodwill and intangibles impairment testing
4. Compensation expense estimation (carry-pool comp accruals)
5. Income tax provision (Up-C related TRA liability)

Each of these involves management judgment but is well-disclosed and follows industry-standard treatment.

GAAP vs Non-GAAP Bridge

ARES management directs investors to Fee-Related Earnings (FRE), Realized Income (RI), and Distributable Earnings (DE) as the primary economic measures, with full reconciliations to GAAP net income in the earnings releases [S4][S8] and 10-K [S2].

Measure	FY2025	What it is
GAAP Total Revenues	$4,756M	Includes management fees + perf fees + investment income + gross-ups
GAAP Net Income	$527M	Includes Consolidated Fund swings + non-cash items
Total Fee-Related Revenue (non-GAAP, segment)	~$3,800M	Management fees + recurring fee streams
Fee-Related Earnings (FRE)	~$2,005M (FY25 est)	Recurring management-fee-driven profitability
FRE Margin	41.7%	Below FY23 43%+ peak; mild compression
Realized Income (RI)	~$1,990M (FY25 est)	Including realized perf fees + Aspida income
Distributable Earnings (DE)	~$1,640M	Cash basis ARES can distribute
DE per share	$4.97	Per total economic interest share count

GAAP-to-non-GAAP bridges in 10-K Note 19 (segment reporting) and earnings releases are clear and consistent quarter to quarter.

Consolidated Funds (the Single Biggest GAAP Distortion)

ARES is required to consolidate certain CLOs and investment vehicles where it has economic exposure that qualifies as a controlling financial interest under US GAAP. This adds approximately:

• $20B+ of CLO loan investments to assets
• $15B+ of CLO notes to liabilities
• $4-5B of non-controlling-interest equity (third-party LP capital)
• Quarter-to-quarter fair-value mark-to-market swings that inflate and deflate "revenues" and "expenses" symmetrically

This is why GAAP operating income was only $47M FY2025 while the underlying economic earnings (DE) were $1.64B [S3][S2]. The 33× delta is entirely driven by Consolidated Funds gross-up — not a quality concern but a structural feature of asset-manager accounting.

Statement-Quality Adjustments (Material Items)

1. Revenue recognition on performance fees — recognized only when the realization event occurs (i.e., when the fund makes a distribution above the hurdle rate). Conservative. NAPI on balance sheet shows accrued-but-unrealized carry; this is real economic value not yet through the P&L.

2. Performance-fee compensation expense — paid out to deal-team carry-pool participants. ARES discloses this on a gross-up basis with the underlying performance income. Comp ratio ~50% [A10]. This is industry standard.

3. Stock-based compensation — ARES SBC ~$300-400M annually (Up-C structure compensates partners via various instruments). This is real economic expense and should be deducted from any "true" earnings calculation. ARES does NOT include SBC in DE, which is a fair criticism — but consensus and peers all use the same convention.

4. Up-C / TRA structure — Up-C corporate structure means ~25-30M AOG units are exchangeable into Class A shares; conversion triggers a Tax Receivable Agreement (TRA) liability obligating ARES to pay ~85% of resulting tax savings to historical AOG unitholders. This creates a cash leakage of ~$50-100M annually. Documented in MD&A but easy to miss in summary metrics [S2].

5. Series B Mandatory Convertible Preferred — ~$1.0B face value; converts to common shares in 2027 at a fixed price band. Adds ~3-4% dilution at conversion. Documented; not hidden [S5].

6. Goodwill + intangibles step-up from GCP — As noted, $3.4B incremental; subject to annual impairment testing. No impairment indicators at FY2025 close but worth tracking.

Adversarial Research Sweep

Short reports: None specific to ARES identified. Hindenburg, Muddy Waters, Spruce Point — none have published on ARES. Broader sector criticism exists (Fortune $265B private credit panic [S11], commentary by certain credit hedge funds questioning industry NAVs) but no firm-specific short report.

SEC enforcement actions: None against ARES or its officers in the past 5 years per EDGAR search.

SEC private fund adviser rules: The 2023 SEC private fund adviser rulemaking was largely vacated by the 5th Circuit in mid-2024 [S15]. Remaining regulatory risk is modest.

Lawsuits / litigation: Routine industry litigation only — no material adverse outcomes per 10-K disclosures [S2]. Standard derivative suits, ERISA-related claims that have been resolved or are immaterial.

Whistleblower / governance issues: None identified.

Insider trading scrutiny: Programmatic 10b5-1 selling by founders (Ressler, Arougheti, Rosenthal, Kaplan) is ongoing and disclosed; no Form 4 anomalies or off-program sales suggesting non-public information advantage [S10].

Activist short positions: None reported in 13F filings or short-interest data; ARES short interest is low (~2-3% of float).

Industry-wide bear narratives:

• Fortune March 2026 "$265B private credit meltdown" — sector-wide [S11]
• Bain & Company, Bridgewater, certain credit hedge funds — generic NAV-questioning of private credit
• Citi research notes (referenced in news flow) — cautious on alternative manager multiples
• None of these are ARES-specific

Operating Cash Flow Quality

Period	GAAP CFO	DE	Convergence Quality
FY2023	-$233M	~$1.5B	Wide divergence (Consolidated Funds + working capital)
FY2024	$2,791M	~$1.55B	CFO > DE (CLO inflows boosted CFO)
FY2025	$3,267M	~$1.64B	CFO > DE (similar pattern)

CFO consistently exceeds DE in recent years because CLO note issuance and certain capital activities are reported as operating cash flow under GAAP. The economic-cash measure (DE) is more conservative — the right number for dividend-coverage analysis.

Dividend Coverage

Q1 2026 dividend: $1.35/sh × ~329.5M total economic shares ≈ $445M paid out. Q1 2026 DE: ~$410M (extrapolated from RI/sh of $1.24) — dividend slightly above DE for Q1 alone.

This is consistent with management's quarterly dividend policy (constant or modestly rising per share) and the typical seasonality where Q4 is the high earnings quarter (carry-harvest weighted). On a trailing-12-month basis dividend coverage is ~110-115%, healthy but not generous. Watch for any year where DE coverage falls below 100%.

Evidence and Sources

• Auditor + clean restatement record: ARES 10-K FY2025 [S2]
• GAAP-to-non-GAAP bridges: 10-K Note 19 + each quarterly Ex 99.2 [S2][S4][S8]
• Consolidated Funds quantum: Q1 2026 10-Q balance sheet detail [S3]
• 5th Circuit vacatur of SEC private fund rules: industry coverage [S15]

Assumption Register Updates

No new assumptions added. A10 (perf-fee comp ratio ~50%) and A20 (DE/equity ~25-30%) already capture key estimates.

Tables and Calculations

See GAAP-vs-non-GAAP bridge table and cash flow convergence table above.

Open Questions and Data Gaps

1. SBC on a DE basis — ARES (like peers) excludes from DE; the "true" cash-economic return is somewhat lower than headline DE per share
2. GCP impairment risk — Watch for any indicators in FY2026/2027 10-K MD&A
3. Performance-fee comp ratio — Industry estimates ~50%; actual is not always cleanly disclosed
4. Consolidated Funds expansion — Will continue to scale with CLO platform growth; not a problem per se but inflates GAAP-vs-economic divergence

Next-Step Dependencies

Step 06 (balance sheet & dilution) deepens the analysis of goodwill, intangibles, debt, and per-share dilution. Step 07 (capital allocation) examines the GCP deal in detail. Step 13 (forecast under /complete-coverage) will model FRE margin trajectory — any compression below 40% would be a thesis revision trigger.

Source Index

Tag	Document or URL	Section / Page / Slide	Date	Notes
[S2]	ARES 10-K FY2025	Notes 2 (acctg policies), 19 (segment), MD&A	2026-02-25	Auditor, statements, bridges
[S3]	SEC XBRL companyfacts	Balance sheet line items	2026-05-28	Consolidated Funds quantum
[S4]	ARES Q1 2026 Ex 99.2	Reconciliations pp 18-22	2026-05-01	Quarterly GAAP→non-GAAP
[S5]	ARES 10-K FY2024	Note 12 Preferred Stock	2025-02-27	Series B mandatory convertible
[S8]	ARES Q4 2025 release	FY25 FRE margin 41.7%	2026-02	Margin compression context
[S10]	SEC Form 4 + insider trackers	12-month activity	2026-05-28	0 open-market buys (March 2026 drawdown)
[S11]	Fortune	"$265B private credit meltdown"	2026-03-14	Sector-wide adversarial narrative
[S15]	AGM Alts Weekly + industry coverage	5th Circuit vacatur	2024-mid	SEC private fund rules vacated

---

ticker: ARES step: 12 generated: 2026-05-28 source: coverage-next-full (transcript-free)

ARES — Step 12: Bull vs Bear — Analyst Debate Synthesis

Key Findings

ARES sits at a clear bull-vs-bear inflection as of late May 2026: the bull thesis is durable ~20% AUM/DE CAGR, perpetual capital inflection through 40%+, Aspida flywheel maturation, and a record Q1 26 fundraising print [S4] vs the bear thesis of private-credit overcapacity / "$265B meltdown" multiple compression [S11], FRE margin creep risk, and Up-C/TRA cash leakage. The stock trades at ~14× P/DE versus a peer median of 16-22× [S12][S15] — implying the bear case is partly priced in, but not fully. Consensus 12-month target is ~$179 (vs $108 spot in early May 2026 = ~66% upside) [S12] — sell-side modally constructive but with high dispersion. The variant perception (per Step 16) is that the market is under-pricing ARES's perpetual capital inflection and Aspida flywheel — these are slow-build optionality that compounds over 3-5 years. Net constructive bias on the multi-year horizon, with credit-cycle clarity required for full conviction in the 12-month frame.

Implications for Thesis and Valuation

1. Probability-weighted scenarios: Bull 35% × $200+ + Base 45% × $150-170 + Bear 20% × $90-110 = Expected value ~$155 (vs $108 spot ≈ +44%).
2. Multi-year (3-5 year) thesis is stronger than 12-month — perpetual capital + Aspida maturation are time-dependent value drivers.
3. Entry timing matters — at $108 the risk/reward is favorable but credit-cycle clarity (a few more quarters of fundraising data + private credit fund stability) would tighten the bear case.
4. The bear case is largely sector-wide, not ARES-specific — which both limits ARES-specific catalyst risk and means ARES rallies on sector recovery.
5. Q4 26 / FY26 carry-harvest cycle is the most material near-term catalyst — management has signaled FY26 should be a strong harvest year [S2].

Objective

Synthesize the bull-vs-bear analyst debate using filings, press releases, consensus commentary, and sector news (no transcripts loaded). Frame the debate so that Step 15 (scenarios under /complete-coverage) can build out the explicit scenario analysis.

Narrative Analysis

What the Bulls Believe

Core bull thesis (composite from sell-side notes, public.com / etoro analyst views, AGM Alts Weekly [S12][S15]):

1. AUM growth at ~20% CAGR is durable through FY28 — record Q1 26 fundraising ($29.5B) + shadow AUM ($80B+) + perpetual capital additions provide multi-year fee-revenue visibility [S4].

2. Perpetual capital inflection — moving from 32% (YE25) to management aspiration of 40%+ over 3-5 years would materially de-risk the fee base and warrant a higher multiple. The market has not fully priced this.

3. FRE margin holds or expands — currently 41-43%; operating leverage on incremental FPAUM at 80%+ marginal margin → FY27-28 FRE margin could reach 45%+.

4. Aspida insurance flywheel — sub-scale today (~$15-20B) vs APO/Athene ($300B+) but trajectory is right. At maturity, Aspida adds ~$300-500M of incremental annualized revenue.

5. GCP integration delivers synergies — FY26 first full year; cross-selling + scale benefits in Real Assets + Asia footprint creates incremental fee revenue.

6. Capital allocation discipline — 22% dividend CAGR, no goodwill impairments, accretive M&A track record.

7. Multiple should re-rate — ARES at 14× P/DE is below peer median 16-22×; sector recovery from the private-credit overhang should lift multiples toward 16-18× range.

Bull case target: $200+ (+85%+ upside from $108).

What the Bears Believe

Core bear thesis (composite from Fortune coverage, Simply Wall Street margin-compression flags, bear-side sector commentary [S11][S15]):

1. Private credit cycle stress is real and worsening — Fortune's "$265B meltdown" is the leading sector narrative; if specific ARES-managed funds run into NAV / redemption stress (none publicly identified yet, but ARES has $400B+ credit AUM = lots of fund-level potential exposure), multiples re-rate down sharply.

2. Direct-lending spread compression — 25-75 bps over 18-24 months means $300M-$700M revenue impact on a $300B+ direct-lending FPAUM base. Material to FRE.

3. FRE margin compression risk — Simply Wall Street flagged incentive comp ratio creep in Q1 26; if this trend continues, FRE margin could erode toward 38-40% over 4-6 quarters.

4. Up-C / TRA cash leakage — ~$50-100M/yr drag on cash-economic returns; DE overstates true returns to common.

5. Insider activity neutral-to-negative — 0 open-market buys during the March 2026 drawdown when stock was at ~$95 = no management conviction signal.

6. Industry overcapacity is fundamental, not cyclical — too much LP capital allocated to alts (~25% target vs ~10% historic); risk of LP allocation moderation if 1-2 years of mediocre returns materialize.

7. Aspida lag vs APO/Athene — ARES is materially behind the curve on insurance flywheel; this is not a near-term catalyst.

Bear case target: $90-110 (flat to -15% from $108).

Variant Perception (preview of Step 16)

Market under-pricing:

• Aspida flywheel maturation (3-5 year compounding)
• Perpetual capital % of AUM crossing 40% inflection
• Shadow AUM ($80B+) providing 12-18 months fee-revenue visibility
• GCP cross-selling synergies (FY26-27)

Market over-pricing (i.e., bear is partially right):

• ARES's resilience to private-credit cycle
• FRE margin sustainability at 42%+

The variant view: market is conflating ARES's sector-wide multiple compression with ARES-specific fundamental risk, when in fact ARES's fundamental drivers are intact and the perpetual capital / Aspida optionality is real.

Near-Term Catalysts (12-Month)

Catalyst	Probability	Direction	Magnitude
Q2 26 / Q3 26 fundraising trajectory	High (Aug + Nov 2026 prints)	Positive if maintained	Medium
FY26 carry-harvest realization	Multi-quarter	Positive if delivered	High
Private-credit sector stability vs further stress	Q1-Q4 26	Bidirectional	Very High
GCP synergies first-year evidence	Q4 26 / FY26 print	Positive if visible	Medium
Aspida AUM / contribution	Steady quarterly	Positive trajectory	Low-Medium
Macro / Fed rate trajectory	Ongoing	Modest negative	Low
Specific private credit fund stress at ARES	Tail	Negative if it occurs	Very High

Consensus Frame

Source	Target ($)	Rating Distribution
public.com / etoro aggregated	$179 (mean)	~75% Buy / 20% Hold / 5% Sell [S12]
Range	$130 (low) — $230 (high)	High dispersion reflects bull/bear divide
ARES FY26E DE/sh consensus	~$6.0-6.5 [A24]	—
Implied FY26E P/DE @ target	~28× (high end) / ~22× (mean)	—

Consensus expects multi-year multiple expansion AND DE/sh growth.

Synthesis

The bull and bear cases are both partially right. The bull's emphasis on durable platform fundamentals + perpetual capital inflection + Aspida flywheel is supported by Q1 26 data and the 3-5 year structural setup. The bear's emphasis on credit-cycle stress + FRE margin creep + multiple compression risk is supported by sector data and reasonable concerns about NAV / spread dynamics.

The disagreement is largely about the time-horizon and resolution path:

• Multi-year (3-5 years) — bulls have the edge on structural drivers
• 12-month (FY26) — heavily dependent on credit-cycle resolution

Recommended stance (anticipating Step 18): Constructive multi-year thesis at current ~$108; appropriate sizing reflects credit-cycle uncertainty; add aggressively on credit-cycle clarity or further weakness toward $90-100.

Evidence and Sources

• Private credit panic: Fortune March 2026 [S11]
• Q1 26 fundraising record: ARES Q1 26 release [S4]
• Consensus target + rating distribution: public.com / etoro / stockanalysis aggregated [S12]
• FRE margin trajectory: Q4 25 + Q1 26 releases [S4][S8]
• Margin compression watch: Simply Wall Street post-Q1 26 [S15]
• Insider activity: SEC Form 4 [S10]

Assumption Register Updates

Existing A25 (Bull case AUM CAGR 18-22%) and A26 (Bear case AUM CAGR 5-10%) anchor scenarios. No new entries.

Tables and Calculations

See bull thesis breakdown, bear thesis breakdown, catalyst table, and consensus frame above.

Open Questions and Data Gaps

1. Magnitude of any specific ARES-managed credit fund stress — None publicly identified but ARES manages 200+ funds; tail risk exists
2. GCP synergy quantification — Will not be fully visible until late FY26
3. Fed rate cut path — Currently ~150 bps of cuts priced in FY26; outcome uncertain
4. LP allocation shift in 2026-2027 — Sustainability of ~25% target allocation TBD

Next-Step Dependencies

Step 16 (variant perception) deepens the under-pricing and over-pricing analysis. Step 15 (scenarios under /complete-coverage) builds explicit quantitative scenarios. Step 18 (portfolio fit) translates bull-bear synthesis into position sizing and entry-timing recommendations.

Source Index

Tag	Document or URL	Section / Page / Slide	Date	Notes
[S2]	ARES 10-K FY2025	MD&A forward commentary	2026-02-25	FY26 harvest cycle framing
[S4]	ARES Q1 2026 Ex 99.2	Q1 26 print	2026-05-01	Fundraising record + FRE momentum
[S8]	ARES Q4 2025 release	Q4 25 miss + FY25 results	2026-02	Bear-side data point
[S10]	SEC Form 4 + insider trackers	T12M activity	2026-05-28	Insider buy = 0 signal
[S11]	Fortune	"$265B private credit meltdown"	2026-03-14	Bear narrative source
[S12]	Street consensus aggregated	public.com / etoro	2026-05	Target + rating distribution
[S15]	AGM Alts Weekly + Simply Wall Street	Industry + margin watch	2026-05	Bull + bear synthesis context

---

Bull Case — 3 bullets

1. Durable ~20% AUM / DE CAGR through FY28. Record Q1 26 fundraising ($29.5B, +48% YoY) + $80B+ shadow AUM + perpetual capital additions provide multi-year fee-revenue visibility. FRE +26% YoY at $464.4M shows operating leverage intact [S4]. AUM trajectory to ~$1T over 3-5 years is plausible.

2. Perpetual capital inflection 32% → 40%+ over 3-5 years would warrant a 20%+ multiple re-rating. ARES currently trades at ~14× P/DE vs peer median 16-22×; OWL at 80% perpetual capital trades at 22× — the perpetual capital math drives sustained re-rating [S12][S15]. Aspida flywheel ($15-20B → $40-50B+) adds incremental durable revenue.

3. GCP synergies + Asia momentum + carry-harvest cycle hit in FY26. First full year of GCP International contribution doubles Real Assets AUM impact; carry-harvest cycle expected to be strong; cross-selling between ARES and GCP LP bases delivers additional fundraising tailwind. Capital allocation discipline (22% dividend CAGR, no impairments, accretive M&A) supports the thesis [S2][S14].

Bear Case — 3 bullets

1. Private credit cycle stress and the "$265B meltdown" narrative compress multiples sector-wide. Direct-lending spread compression of 25-75 bps over 18-24 months → $300M-$700M revenue impact on $300B+ direct-lending FPAUM base; LP allocation appetite could moderate if 1-2 years of mediocre sector returns materialize. ARES at 14× P/DE may re-rate down further toward 11-13× if specific ARES-managed credit funds run into NAV / redemption stress [S11][A23].

2. FRE margin compression from rising incentive comp ratios. Simply Wall Street flagged Q1 26 incentive comp ratio creep — if this trend continues, FRE margin could erode from 41-43% toward 38-40% over 4-6 quarters, materially compressing the operating leverage thesis [S15]. The Q4 25 miss already showed performance harvest timing variance is a real downside risk.

3. Up-C / TRA cash leakage + lack of insider conviction signal mild bear. ~$50-100M/yr TRA payments are real cash drag that DE overstates; ongoing AOG unit exchanges + ~$1B Series B Preferred conversion add per-share dilution; insider 0 open-market buys during the March 2026 drawdown when stock traded ~$95 = no management conviction signal at currently mid-range valuation [S9][S10]. Aspida lag vs APO/Athene means insurance flywheel is not a near-term catalyst.